Merck pays $50mm cash up front in new viral disease mRNA deal with Moderna; Agreement Cancelled
Merck & Co. Inc. is entering the messenger-RNA space through a new deal with Moderna Therapeutics LLC aimed at turning out vaccines and passive immunity therapies against viral diseases.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com